Mucus buildup can block the airways in patients with asthma, but the typical treatment fails to reduce the mucus in patients’ lungs. A new research study shows that dupilumab reduces mucus buildup and improves breathing in adults and adolescents with moderate-to-severe asthma as soon as four weeks after treatment.
The study, “Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial” was published online in the American Journal of Respiratory and Critical Care Medicine.
Learn more
